182 related articles for article (PubMed ID: 9758341)
41. Engraftment of primates with G-CSF mobilized peripheral blood CD34+ progenitor cells expanded in G-CSF, SCF and MGDF decreases the duration and severity of neutropenia.
Andrews RG; Briddell RA; Hill R; Gough M; McNiece IK
Stem Cells; 1999; 17(4):210-8. PubMed ID: 10437984
[TBL] [Abstract][Full Text] [Related]
42. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
[TBL] [Abstract][Full Text] [Related]
43. Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness.
Faucher C; le Corroller AG; Blaise D; Novakovitch G; Manonni P; Moatti JP; Maraninchi D
Bone Marrow Transplant; 1994 Dec; 14(6):895-901. PubMed ID: 7536070
[TBL] [Abstract][Full Text] [Related]
44. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
[TBL] [Abstract][Full Text] [Related]
45. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.
Yoon DH; Sohn BS; Jang G; Kim EK; Kang BW; Kim C; Kim JE; Kim S; Lee DH; Lee JS; Park SJ; Park CJ; Huh J; Suh C
Transfusion; 2009 Sep; 49(9):1890-900. PubMed ID: 19453991
[TBL] [Abstract][Full Text] [Related]
46. Pediatric experience with autologous peripheral blood progenitor cell transplantation: influence of CD34+ cell dose in engraftment kinetics.
Diaz MA; Alegre A; Villa M; Granda A; de la Vega A; Ramirez M; Ruano D; Gonzalez A; Merino JM; Madero L
Bone Marrow Transplant; 1996 Oct; 18(4):699-703. PubMed ID: 8899183
[TBL] [Abstract][Full Text] [Related]
47. G-CSF post-autologous progenitor cell transplantation: a randomized study of 5, 10, and 16 micrograms/kg/day.
Bolwell B; Goormastic M; Dannley R; Andresen S; Overmoyer B; Mendez Z; Kalaycioglu M; DeMars D; Wise K; Pohlman B
Bone Marrow Transplant; 1997 Feb; 19(3):215-9. PubMed ID: 9028548
[TBL] [Abstract][Full Text] [Related]
48. Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma.
Tomblyn M; Burns LJ; Blazar B; Wagner J; Lee C; Rogers T; McGlave P; Miller JS; Weisdorf DJ
Bone Marrow Transplant; 2007 Jul; 40(2):111-8. PubMed ID: 17530003
[TBL] [Abstract][Full Text] [Related]
49. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
50. Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery.
Dreger P; Viehmann K; von Neuhoff N; Glaubitz T; Petzoldt O; Glass B; Uharek L; Rautenberg P; Suttorp M; Mills B; Mitsky P; Schmitz N
Bone Marrow Transplant; 1999 Jul; 24(2):153-61. PubMed ID: 10455343
[TBL] [Abstract][Full Text] [Related]
51. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
Klaus J; Herrmann D; Breitkreutz I; Hegenbart U; Mazitschek U; Egerer G; Cremer FW; Lowenthal RM; Huesing J; Fruehauf S; Moehler T; Ho AD; Goldschmidt H
Eur J Haematol; 2007 Jan; 78(1):21-8. PubMed ID: 17042762
[TBL] [Abstract][Full Text] [Related]
52. Factors influencing collection and engraftment of CD34+ cells in patients with breast cancer following high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation.
Canales MA; Arrieta R; Hernández-García MC; Ojeda E; Díez J; Calero F; Aguado MJ; Bustos JG; Hernández-Navarro F
J Hematother Stem Cell Res; 2000 Feb; 9(1):103-9. PubMed ID: 10738978
[TBL] [Abstract][Full Text] [Related]
53. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
54. Posttransplant thrombopoiesis predicts survival in patients undergoing autologous hematopoietic progenitor cell transplantation.
Ninan MJ; Flowers CR; Roback JD; Arellano ML; Waller EK
Biol Blood Marrow Transplant; 2007 Aug; 13(8):895-904. PubMed ID: 17640593
[TBL] [Abstract][Full Text] [Related]
55. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens.
Stewart DA; Guo D; Morris D; Poon MC; Ruether BA; Jones AR; Klassen J; Auer I; Luider J; Chaudhry A; Brown C; Russell JA
Bone Marrow Transplant; 1999 Jan; 23(2):111-7. PubMed ID: 10197794
[TBL] [Abstract][Full Text] [Related]
56. CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients.
Kasow KA; Sims-Poston L; Eldridge P; Hale GA
Biol Blood Marrow Transplant; 2007 May; 13(5):608-14. PubMed ID: 17448921
[TBL] [Abstract][Full Text] [Related]
57. Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods.
Venditti A; Battaglia A; Del Poeta G; Buccisano F; Maurillo L; Tamburini A; Del Moro B; Epiceno AM; Martiradonna M; Caravita T; Santinelli S; Adorno G; Picardi A; Zinno F; Lanti A; Bruno A; Suppo G; Franchi A; Franconi G; Amadori S
Bone Marrow Transplant; 1999 Nov; 24(9):1019-27. PubMed ID: 10556963
[TBL] [Abstract][Full Text] [Related]
58. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis.
Pettengell R; Morgenstern GR; Woll PJ; Chang J; Rowlands M; Young R; Radford JA; Scarffe JH; Testa NG; Crowther D
Blood; 1993 Dec; 82(12):3770-7. PubMed ID: 7505124
[TBL] [Abstract][Full Text] [Related]
59. Quantification of CD34+ cells mobilized into the peripheral blood predicts the yield of the leukapheresis product and can replace progenitor assays.
D'Hondt L; André M; Guillaume T; Feyens AM; Humblet Y; Doyen C; Bosly A; Dromelet A; Chatelain B; Symann M
Cytokines Cell Mol Ther; 1997 Mar; 3(1):21-6. PubMed ID: 9287240
[TBL] [Abstract][Full Text] [Related]
60. A simplified method of CD34+ cell determination for peripheral blood progenitor cell transplantation and correlation with clinical engraftment.
Sandhaus LM; Edinger MG; Tubbs RR; Goormastic M; Baucco PA; Serafino SE; Bolwell BJ
Exp Hematol; 1998 Jan; 26(1):73-8. PubMed ID: 9430516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]